fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Buprenorphine

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription

Sublocade · DIN 02483084 · 100 mg/0.5 mL · injection solution- 0.5mL pre-filled syringe

General benefitMarketed · checked November 18, 2026
Write on scriptno code needed

Free naloxone kits in Ontario: no prescription or health card needed; free kits at participating pharmacies and community sites

Free naloxone kits: eligibility and access
No interchangeable product listed in the Ontario extract
Sublocade · DIN 02483084 Manufacturer: Indivior UK Limited; listing date 2020-04-30 Health Canada: Marketed since 2020-02-03 · brand SUBLOCADE · ATC N07BC01 BUPRENORPHINE · form Solution (extended-release) · route Subcutaneous · ingredients BUPRENORPHINE 100 MG/0.5ML · company Indivior uk limited · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Sublocade: Formulary list price $550.00 per unit (the source does not state the unit; exact figure $550.0000). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02483084)

Source record
DIN 02483084: Sublocade Raw flags: sec3=Y Item: 280812024; group id 414; item number 1019; lccId None; manufacturer id IND Source form: Inj Sol- 0.5mL Pref Syr; strength: 100mg/0.5mL Recorded listing: General benefit Source prices (unrounded): $550.0000; ministry $550.0000 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02483084 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97348
Shortage status: resolved shortage (ended March 9, 2021); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02483084
Shortage record checked October 6, 2026

Sublocade · DIN 02483092 · 300 mg/1.5 mL · injection solution- 1.5mL pre-filled syringe

General benefitMarketed · checked November 18, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Sublocade · DIN 02483092 Manufacturer: Indivior UK Limited; listing date 2020-04-30 Health Canada: Marketed since 2020-02-03 · brand SUBLOCADE · ATC N07BC01 BUPRENORPHINE · form Solution (extended-release) · route Subcutaneous · ingredients BUPRENORPHINE 300 MG/1.5ML · company Indivior uk limited · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Sublocade: Formulary list price $550.00 per unit (the source does not state the unit; exact figure $550.0000). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02483092)

Source record
DIN 02483092: Sublocade Raw flags: sec3=Y Item: 280812025; group id 414; item number 1020; lccId None; manufacturer id IND Source form: Inj Sol- 1.5mL Pref Syr; strength: 300mg/1.5mL Recorded listing: General benefit Source prices (unrounded): $550.0000; ministry $550.0000 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02483092 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97349
Shortage status: resolved shortage (ended March 2, 2022); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02483092
Shortage record checked October 6, 2026

Buprenorphine hydrochloride

All products: Limited Use (codes 578)

Probuphine · DIN 02474921 · 80 mg · Subdermal Implant-Kit Pk

Limited Use, Reason for Use code 578 required; Health Canada lists this DIN as Cancelled post market since 2023-06-30 — choose a marketed DIN from the same-category list.Discontinued June 30, 2023 · checked October 5, 2026
StatusLimited Use, Reason for Use code 578 required; Health Canada lists this DIN as Cancelled post market since 2023-06-30 — choose a marketed DIN from the same-category list.
Write on scriptReason for Use code 578 (criteria below); Health Canada lists this DIN as Cancelled post market since 2023-06-30 — choose a marketed DIN from the same-category list.
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 578
Reason for Use code 578 For the management of opioid use disorder in combination with counseling and psychosocial support in adult patients who meet the following criteria: - The patient is stabilized on a dose of no more than 8mg per day of sublingual buprenorphine for the preceding 90 days; AND - The patient is under the care of a health care provider with experience in the diagnosis and management of opioid use disorder and has been trained to implant and remove the buprenorphine subdermal implant. Recommended dose: Four 80mg implants inserted subdermally in the inner side of the upper arm for up to six months. The maximum quantity that can be claimed per patient is four (4) implant cycles (i.e. two (2) years of therapy). NOTE: The product monograph indicates that dosing beyond two (2) years cannot be recommended at this time. Probuphine subdermal implants are intended to be in place for six months of treatment. Probuphine implants are removed at the end of the six-month period. If continued treatment is desired, the implants should be replaced by new implants (implanted in the opposite arm) at the time of removal. Coverage limit: LU Authorization Period: 2 years
No interchangeable product listed in the Ontario extract
Probuphine · DIN 02474921 Manufacturer: Knight Therapeutics Inc.; listing date 2020-04-30 Health Canada: Cancelled post market since 2023-06-30 · brand PROBUPHINE · ATC N07BC01 BUPRENORPHINE · form Implant · route Subcutaneous · ingredients BUPRENORPHINE HYDROCHLORIDE 80 MG · company Knight therapeutics inc. · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Probuphine: Formulary list price $1495.00 per unit (the source does not state the unit; exact figure $1495.0000). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02474921)

Source record
DIN 02474921: Probuphine Raw flags: sec12=Y, sec3=Y Item: 280812023; group id 416; item number 1027; lccId 00333; manufacturer id KNT Source form: Subdermal Implant-Kit Pk; strength: 80mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1495.0000; ministry $1495.0000 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02474921 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96515
Shortage status: discontinued (July 3, 2023, reported by KNIGHT THERAPEUTICS INC.); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02474921
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since June 30, 2023 — choose a marketed DIN from the same-category list.

Buprenorphine & naloxone

Form:

10 of 10 products shown

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription

Act Buprenorphine/Naloxone · DIN 02453908 · 2 mg & 0.5 mg · SL tablet

General benefitMarketed · checked November 18, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Act Buprenorphine/Naloxone · DIN 02453908 Manufacturer: Actavis Pharma Company; listing date 2018-01-31 Health Canada: Marketed since 2021-03-22 · brand TEVA-BUPRENORPHINE/NALOXONE · ATC N07BC51 BUPRENORPHINE, COMBINATIONS · form Tablet · route Sublingual · ingredients BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 2 MG, NALOXONE (NALOXONE HYDROCHLORIDE DIHYDRATE) 0.5 MG · company Teva canada limited · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Act Buprenorphine/Naloxone: Formulary list price $1.34 per unit (the source does not state the unit; exact figure $1.3350). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02453908)

Source record
DIN 02453908: Act Buprenorphine/Naloxone Raw flags: sec3=Y Item: 280812006; group id 415; item number 1021; lccId None; manufacturer id ACV Source form: SL Tab; strength: 2mg & 0.5mg Recorded listing: General benefit Source prices (unrounded): $1.3350; ministry $1.3350 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02453908 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94043
Interchangeable products
PMS-Buprenorphine-Naloxone · DIN 02424851 · $1.3350 Suboxone · DIN 02295695 · $1.3350
Shortage status: resolved shortage (ended April 8, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02453908
Shortage record checked October 6, 2026

PMS-Buprenorphine-Naloxone · DIN 02424851 · 2 mg & 0.5 mg · SL tablet

General benefitMarketed · checked November 18, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-Buprenorphine-Naloxone · DIN 02424851 Manufacturer: Pharmascience Inc.; listing date 2015-02-26 Health Canada: Marketed since 2017-11-24 · brand PMS-BUPRENORPHINE-NALOXONE · ATC N07BC51 BUPRENORPHINE, COMBINATIONS · form Tablet · route Sublingual · ingredients BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 2 MG, NALOXONE (NALOXONE HYDROCHLORIDE DIHYDRATE) 0.5 MG · company Pharmascience inc · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

PMS-Buprenorphine-Naloxone: Formulary list price $1.34 per unit (the source does not state the unit; exact figure $1.3350). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02424851)

Source record
DIN 02424851: PMS-Buprenorphine-Naloxone Raw flags: sec3=Y Item: 280812006; group id 415; item number 1021; lccId None; manufacturer id PMS Source form: SL Tab; strength: 2mg & 0.5mg Recorded listing: General benefit Source prices (unrounded): $1.3350; ministry $1.3350 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02424851 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90952
Interchangeable products
Act Buprenorphine/Naloxone · DIN 02453908 · $1.3350 Suboxone · DIN 02295695 · $1.3350
Shortage status: resolved shortage (ended October 4, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02424851
Shortage record checked October 6, 2026

Suboxone · DIN 02295695 · 2 mg & 0.5 mg · SL tablet

General benefitMarketed · checked November 18, 2026
Write on scriptno code needed
1 brand, same coverage
Suboxone · DIN 02295695 Manufacturer: Indivior UK Limited; listing date 2012-10-30 Health Canada: Marketed since 2016-03-10 · brand SUBOXONE · ATC N07BC51 BUPRENORPHINE, COMBINATIONS · form Tablet · route Sublingual · ingredients BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 2 MG, NALOXONE (NALOXONE HYDROCHLORIDE DIHYDRATE) 0.5 MG · company Indivior uk limited · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02295695)

Source record
DIN 02295695: Suboxone Raw flags: sec3=Y Item: 280812006; group id 415; item number 1021; lccId None; manufacturer id IND Source form: SL Tab; strength: 2mg & 0.5mg Recorded listing: General benefit Source prices (unrounded): $2.7261; ministry $1.3350 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02295695 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78104
Interchangeable products
Act Buprenorphine/Naloxone · DIN 02453908 · $1.3350 PMS-Buprenorphine-Naloxone · DIN 02424851 · $1.3350
Shortage status: To be discontinued; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02295695
Shortage record checked October 6, 2026

Suboxone · DIN 02502313 · 2 mg & 0.5 mg · Soluble Film

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Suboxone · DIN 02502313 Manufacturer: Indivior UK Limited; listing date 2024-05-31 Health Canada: Marketed since 2021-01-20 · brand SUBOXONE · ATC N07BC51 BUPRENORPHINE, COMBINATIONS, N07BC51 BUPRENORPHINE, COMBINATIONS · form Film (soluble) · route Buccal, Sublingual · ingredients BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 2 MG, NALOXONE (NALOXONE HYDROCHLORIDE) 0.5 MG · company Indivior uk limited · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Suboxone: Formulary list price $2.67 per unit (the source does not state the unit; exact figure $2.6700). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02502313)

Source record
DIN 02502313: Suboxone Raw flags: sec3=Y Item: 280812032; group id 415; item number 1023; lccId None; manufacturer id IND Source form: Soluble Film; strength: 2mg & 0.5mg Recorded listing: General benefit Source prices (unrounded): $2.6700; ministry $2.6700 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02502313 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99189
Shortage status: resolved shortage (ended April 28, 2023); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02502313
Shortage record checked October 6, 2026

Suboxone · DIN 02502321 · 4 mg & 1 mg · Soluble Film

General benefitMarketed · checked November 18, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Suboxone · DIN 02502321 Manufacturer: Indivior UK Limited; listing date 2026-02-27 Health Canada: Marketed since 2021-06-17 · brand SUBOXONE · ATC N07BC51 BUPRENORPHINE, COMBINATIONS · form Film (soluble) · route Buccal, Sublingual · ingredients BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 4 MG, NALOXONE (NALOXONE HYDROCHLORIDE) 1 MG · company Indivior uk limited · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Suboxone: Formulary list price $3.69 per unit (the source does not state the unit; exact figure $3.6889). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02502321)

Source record
DIN 02502321: Suboxone Raw flags: sec3=Y Item: 280812033; group id 415; item number 1024; lccId None; manufacturer id IND Source form: Soluble Film; strength: 4mg & 1mg Recorded listing: General benefit Source prices (unrounded): $3.6889; ministry $3.6889 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02502321 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99190
Shortage status: resolved shortage (ended July 4, 2023); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02502321
Shortage record checked October 6, 2026

Act Buprenorphine/Naloxone · DIN 02453916 · 8 mg & 2 mg · SL tablet

General benefitMarketed · checked November 18, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Act Buprenorphine/Naloxone · DIN 02453916 Manufacturer: Actavis Pharma Company; listing date 2018-01-31 Health Canada: Marketed since 2021-03-22 · brand TEVA-BUPRENORPHINE/NALOXONE · ATC N07BC51 BUPRENORPHINE, COMBINATIONS · form Tablet · route Sublingual · ingredients BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 8 MG, NALOXONE (NALOXONE HYDROCHLORIDE DIHYDRATE) 2 MG · company Teva canada limited · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Act Buprenorphine/Naloxone: Formulary list price $2.37 per unit (the source does not state the unit; exact figure $2.3650). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02453916)

Source record
DIN 02453916: Act Buprenorphine/Naloxone Raw flags: sec3=Y Item: 280812010; group id 415; item number 1022; lccId None; manufacturer id ACV Source form: SL Tab; strength: 8mg & 2mg Recorded listing: General benefit Source prices (unrounded): $2.3650; ministry $2.3650 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02453916 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94044
Interchangeable products
PMS-Buprenorphine-Naloxone · DIN 02424878 · $2.3650 Suboxone · DIN 02295709 · $2.3650
Shortage status: resolved shortage (ended April 8, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02453916
Shortage record checked October 6, 2026

PMS-Buprenorphine-Naloxone · DIN 02424878 · 8 mg & 2 mg · SL tablet

General benefitMarketed · checked November 18, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-Buprenorphine-Naloxone · DIN 02424878 Manufacturer: Pharmascience Inc.; listing date 2015-02-26 Health Canada: Marketed since 2017-11-24 · brand PMS-BUPRENORPHINE-NALOXONE · ATC N07BC51 BUPRENORPHINE, COMBINATIONS · form Tablet · route Sublingual · ingredients BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 8 MG, NALOXONE (NALOXONE HYDROCHLORIDE DIHYDRATE) 2 MG · company Pharmascience inc · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

PMS-Buprenorphine-Naloxone: Formulary list price $2.37 per unit (the source does not state the unit; exact figure $2.3650). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02424878)

Source record
DIN 02424878: PMS-Buprenorphine-Naloxone Raw flags: sec3=Y Item: 280812010; group id 415; item number 1022; lccId None; manufacturer id PMS Source form: SL Tab; strength: 8mg & 2mg Recorded listing: General benefit Source prices (unrounded): $2.3650; ministry $2.3650 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02424878 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90953
Interchangeable products
Act Buprenorphine/Naloxone · DIN 02453916 · $2.3650 Suboxone · DIN 02295709 · $2.3650
Shortage status: resolved shortage (ended January 16, 2022); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02424878
Shortage record checked October 6, 2026

Suboxone · DIN 02295709 · 8 mg & 2 mg · SL tablet

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
1 brand, same coverage
Suboxone · DIN 02295709 Manufacturer: Indivior UK Limited; listing date 2012-10-30 Health Canada: Marketed since 2016-04-01 · brand SUBOXONE · ATC N07BC51 BUPRENORPHINE, COMBINATIONS, N07BC51 BUPRENORPHINE, COMBINATIONS · form Tablet · route Sublingual · ingredients NALOXONE (NALOXONE HYDROCHLORIDE DIHYDRATE) 2 MG, BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 8 MG · company Indivior uk limited · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02295709)

Source record
DIN 02295709: Suboxone Raw flags: sec3=Y Item: 280812010; group id 415; item number 1022; lccId None; manufacturer id IND Source form: SL Tab; strength: 8mg & 2mg Recorded listing: General benefit Source prices (unrounded): $4.8293; ministry $2.3650 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02295709 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78105
Interchangeable products
Act Buprenorphine/Naloxone · DIN 02453916 · $2.3650 PMS-Buprenorphine-Naloxone · DIN 02424878 · $2.3650
Shortage status: To be discontinued; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02295709
Shortage record checked October 6, 2026

Suboxone · DIN 02502348 · 8 mg & 2 mg · Soluble Film

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Suboxone · DIN 02502348 Manufacturer: Indivior UK Limited; listing date 2024-05-31 Health Canada: Marketed since 2021-01-20 · brand SUBOXONE · ATC N07BC51 BUPRENORPHINE, COMBINATIONS, N07BC51 BUPRENORPHINE, COMBINATIONS · form Film (soluble) · route Buccal, Sublingual · ingredients BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 8 MG, NALOXONE (NALOXONE HYDROCHLORIDE) 2 MG · company Indivior uk limited · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Suboxone: Formulary list price $4.73 per unit (the source does not state the unit; exact figure $4.7300). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02502348)

Source record
DIN 02502348: Suboxone Raw flags: sec3=Y Item: 280812034; group id 415; item number 1025; lccId None; manufacturer id IND Source form: Soluble Film; strength: 8mg & 2mg Recorded listing: General benefit Source prices (unrounded): $4.7300; ministry $4.7300 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02502348 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99191
Shortage status: resolved shortage (ended May 18, 2023); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02502348
Shortage record checked October 6, 2026

Suboxone · DIN 02502356 · 12 mg & 3 mg · Soluble Film

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Suboxone · DIN 02502356 Manufacturer: Indivior UK Limited; listing date 2024-05-31 Health Canada: Marketed since 2021-01-20 · brand SUBOXONE · ATC N07BC51 BUPRENORPHINE, COMBINATIONS, N07BC51 BUPRENORPHINE, COMBINATIONS · form Film (soluble) · route Buccal, Sublingual · ingredients BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 12 MG, NALOXONE (NALOXONE HYDROCHLORIDE) 3 MG · company Indivior uk limited · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Suboxone: Formulary list price $7.10 per unit (the source does not state the unit; exact figure $7.0950). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02502356)

Source record
DIN 02502356: Suboxone Raw flags: sec3=Y Item: 280812031; group id 415; item number 1026; lccId None; manufacturer id IND Source form: Soluble Film; strength: 12mg & 3mg Recorded listing: General benefit Source prices (unrounded): $7.0950; ministry $7.0950 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02502356 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99192
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02502356
Shortage record checked October 6, 2026
Other drugs in the same formulary class (28:08:12 Opiate Partial Agonists) and how they are covered

Matched class: 28:08:12 Opiate Partial Agonists

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over No displayed product is listed as a general benefit in this extract. Check its listing requirements below. 28:08:12 Opiate Partial Agonists

BUTORPHANOL TARTRATE

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 10mg/mL · Nas Sp-2.5mL Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 28:08:12
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:08 Tranquilizers, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS SUBLOCADE (buprenorphine solution (extended-release) for injection) is indicated for the management of moderate to severe opioid use disorder in adult patients. SUBLOCADE should be used as part of a complete treatment plan that includes counselling and psychosocial support. SUBLOCADE must only be administered subcutaneously by a healthcare professional (see 4 DOSAGE AND ADMINISTRATION). 1.1 Pediatrics Pediatrics (˂18 years of age): No data are available in patients under 18 years of age. SUBLOCADE is not indicated in pediatric patients. 1.2 Geriatrics Geriatrics (≥ 65 years of age): There were no patients ≥ 65 years of age in the controlled clinical trial of SUBLOCADE. In general, drug use for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, respiratory and/or cardiac function, concomitant disease or other drug therapies. If the decision is made to prescribe SUBLOCADE to individuals 65 years of age or older, patients should be monitored for signs and symptoms of toxicity or overdose. https://pdf.hres.ca/dpd_pm/00082639.PDF PM date: NOV 20, 2018 Source product: SUBLOCADE; DIN 02483084; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
Product monograph unavailable: no marketed product found
What the Health Canada label says it is for
1 INDICATIONS SUBOXONE® (buprenorphine and naloxone) is indicated for: • substitution treatment in adults with problematic opioid drug dependence. 1.1 Pediatrics Pediatrics (<18 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of SUBOXONE in pediatric patients has not been established; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics (> 65 years of age): The safety and efficacy of SUBOXONE have not been established in adults over 65 years of age. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, respiratory or cardiac function, concomitant disease or other drug therapy. https://pdf.hres.ca/dpd_pm/00069997.PDF PM date: MAY 17, 2007 Source product: SUBOXONE; DIN 02295695; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Probuphine · DIN 02474921 Shortage status: discontinued (2023-07-03, reported by KNIGHT THERAPEUTICS INC.); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02474921

Check this DIN again

Suboxone · DIN 02295695 Shortage status: To be discontinued; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02295695

Check this DIN again

Suboxone · DIN 02295709 Shortage status: To be discontinued; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02295709

Check this DIN again
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18